Post-traumatic Stress Disorder Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Demographics (Adult, Children), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global post-traumatic stress disorder treatment market size was valued at USD 915.5 million in 2021 and is expected to witness a compound annual growth rate (CAGR) of 4.7% from 2022 to 2030. The major factor driving the market includes robust late stage product pipeline and increasing R&D for development of novel therapies pertaining to treatment. Moreover, global rise in burden of post-traumatic stress disorder (PTSD) cases is primarily driving the market. For instance, according to PTSD Statistics and Facts article, about 8 million Americans are suffering from the condition in 2021.

The upsurge in incidence of post-traumatic stress disorder is such that one in 13 people develop this disorder once in lifetime. According to NCBI article, 70% of adult Americans experience at least one traumatic event out of which 20% develop PTSD due to such events. The prevalence of this condition is more common in women than in men due to sexual violence and rape victims which is the leading cause of traumatic experiences. Its prevalence rate among women is around 9.7%, compared to about 3.6% in men. Furthermore, rising incidences of natural and manmade disasters, such as the COVID-19 pandemic and the Russian-Ukraine war, further support the cases.

The increasing demand for better therapeutic options is leading to innovation in R&D, and the introduction of new therapeutic drugs, thereby creating a lucrative opportunity for market growth over the forecast period. For instance, Otsuka Pharmaceutical Development Inc.’s Brexpiprazole and Zoloft Combination is in phase 3 investigation for PTSD. Furthermore, Jazz Pharmaceuticals’ JZP150, Aptinyx’s NYX-783, and Bionomics’ BNC210 are under phase 2 clinical investigation, such factors are expected drive the space growth over the forecast period.

However, side effects associated with post-traumatic stress disorder therapeutics, such as drug abuse, is expected to restrain the space growth over the forecast period.

Drug Class Insights 

The antidepressants drug class segment dominated the PTSD treatment market in 2021. This can be attributed due to the presence of FDA approved SSRIs (selective serotonin reuptake inhibitors) such as Zoloft (sertraline) and Paxil (paroxetine) driving the space. They are recommended as first line of treatment for PTSD. The space also has a high presence of some off-label antidepressant drugs such as Serzone (nefazodone), Nardil (phenelzine), and Tofranil (imipramine) to treat the condition. However, these medications aren’t recommended for initial PTSD treatment. 

Furthermore, key players are strategically undertaking initiatives such as collaborations, expansion, and partnerships to develop drugs and grow in the space. For example, in March 2022, H. Lundbeck A/S entered into licensing agreement for the antidepressant drug Vortioxetine to Sun Pharmaceutical Industries Ltd. Under this agreement, Sun Pharmaceutical Industries Ltd. will sell and distribute Vortioxetine under the brand name Vortidiftm in the Indian market. The key players are also developing and investigating combination therapies, including antidepressant drugs, for managing the condition. For example, Otsuka Pharmaceutical’s Brexpiprazole and Zoloft Combination is under phase 3 studies and expected launch of such combinations is anticipated to fuel the space.

Demographics Insights

The adult segment dominated the market and held 84.5% market share in 2021, owing to major chunk of patients in age group, rising disorder cases in the adult group, and increasing traumatic experiences. The group experience severe, moderate to mild impairment levels of symptoms. According to the research study, in the U.S., in 2021, serious impairment was reported for about 36% of patients, moderate impairment for about 33%, and mild for around 30% of patients. Moreover, childhood trauma also contributes to developing PTSD in adulthood. Furthermore, as reported, adult women have high prevalence of about 5.2% than adult men at about 1.8% for PTSD. Thus, owing to such factors segment is also expected to maintain its dominance over the forecast period.

Pharmacotherapy is prescribed to children who show persistent PTSD symptoms despite undergoing cognitive behavior therapy. There are currently no FDA approved Selective serotonin reuptake inhibitors (SSRIs) for the treatment of PTSD in children. However, growing awareness, increasing understanding of importance of mental health, are contributing to growth of the children demographic segment.

Distribution Channel Insights 

The retail pharmacy segment dominated the market and accounted for the largest revenue share of 64.0% over the forecast period. As post-traumatic stress disorder treatment, control and management take short term as well as long term support of medications which offers retail pharmacies’ growth. In addition, retail pharmacies are at ease for most medications, especially in the homecare setting. All these factors are expected to fuel the market in coming years.

The others segment is expected to witness a CAGR of 3.0% during the forecast period. Presence of online pharmacy platform encourages the comfort of buying. The trend of online purchasing has upsurge due to the ease and home delivery flexibility, generating revenues, thereby driving the segment. Amid pandemic people also experienced the comfort of delivery services and reduce time and travel for prescription refill in retail stores.

Regional Insights

North America dominated the PTSD treatment market and accounted for the largest revenue share of 57.8% in 2021. The major factors driving the space include the rising prevalence of the PTSD and increasing patient awareness about mental health. For instance, according to PTSD statistics and facts, the prevalence of the condition in the U.S. was reported to about 3.6% in adults over 18 years of age. Increased in healthcare expenditure and presence of major players in the region is boosting the growth. Advance therapeutic options with expected new approvals and launches over the forecast period, and proactive government measures further contribute to regional growth.

Asia Pacific is estimated to witness the fastest growth rate in the coming years. The high growth rate can be attributed to rising burden of disorder and the increasing approach of patients to doctors for mental health. Positive changes, such as healthcare benefits by the government, increased awareness among the population, and increased willingness to avail medical treatment are also expected to drive the market in the region.

Key Companies & Market Share Insights

Major players are trying to grow by undertaking various strategic initiatives, such as geographical expansion, merger, and acquisition, in order to gain a higher market share. Moreover, companies are focusing on gaining approvals for novel products with improved efficacy. For instance, in January 2022, Mydecine Innovations Group Inc., Combat Stress and King’s College London entered into a partnership to utilize the psychotherapeutic drug psilocybin to treat PTSD. Some of the prominent players in the post-traumatic stress disorder treatment include:

• Lupin Limited

• Pfizer, Inc.

• Aurobindo Pharma Limited

• Merck KGaA

• GlaxoSmithKline plc.

• Otsuka Pharmaceutical Development

• Jazz Pharmaceuticals

• Bionomics

• Aptinyx         

• AstraZeneca

 Post-traumatic Stress Disorder Treatment Market Report Scope 

Global Post-traumatic Stress Disorder Treatment Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2022 to 2030. For the purpose of this report, Grand View Research has segmented the global post-traumatic stress disorder treatment market report on the basis of drug class, demographics, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Antidepressants

  • Antipsychotics

  • Anti-anxiety

  • Others

• Demographics Outlook (Revenue, USD Million, 2018 - 2030)

  • Adult

  • Children

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • India

    • China

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Argentina

    • Brazil

    • Mexico

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • UAE